Showing results (91-100 of 216) with videos related to

Sort By:
Pageof 22
Cell Death & Disease|March 30, 2024
PQR309, a dual PI3K/mTOR inhibitor, synergizes with gemcitabine by impairing the GSK-3β and STAT3/HSP60 signaling pathways to treat nasopharyngeal carcinomaJiaxin Cao, Kangmei Zeng, Qun Chen, et al.
Translational Lung Cancer Research|July 18, 2020
<i>EGFR</i> mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patientsQiufan Zheng, Yan Huang, Hongyun Zhao, et al.
Frontiers in Oncology|November 27, 2020
Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 StudyShen Zhao, Zhen Zhang, Wenfeng Fang, et al.
Frontiers in Microbiology|April 30, 2026
Synthesis of biochar-supported sulfidated nanoscale zero-valent iron and its application as a persulfate activator for remediation of crude oil-contaminated soilJin Zheng, Yong Zhai, Chunyang Gao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2026
Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global ImplementationJia Liu, Juliana Beal, Niamh Coleman, et al.
Annals of Translational Medicine|April 21, 2020
Clinical pharmacokinetics and drug exposure-toxicity correlation study of docetaxel based chemotherapy in Chinese head and neck cancer patientsYuxiang Ma, Qingguang Lin, Yunpeng Yang, et al.
BMC Medicine|October 1, 2021
Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancerShen Zhao, Zhonghan Zhang, Jianhua Zhan, et al.
Annals of Translational Medicine|February 12, 2020
The analysis of pharmacokinetic and pharmacogenomic impact on gefitinib efficacy in advanced non-small cell lung cancer patients: results from a prospective cohort studyYuxiang Ma, Shuang Xin, Qingguang Lin, et al.
Annals of Medicine|December 8, 2023
Predictive value of immunotherapy-induced inflammation indexes: dynamic changes in patients with nasopharyngeal carcinoma receiving immune checkpoint inhibitorsJiaxin Cao, Qun Chen, Xue Bai, et al.
Scientific Reports|December 2, 2014
A large-scale cross-sectional study of ALK rearrangements and EGFR mutations in non-small-cell lung cancer in Chinese Han populationShaodong Hong, Wenfeng Fang, Zhihuang Hu, et al.
Pageof 22